Therap Human Monoclonal Antibod for Treatment of Hantavirus Cardiopulmonary Syndr

美洲尚未开发出预防HCPS的有效疫苗，治疗方法是 目前仅限于支持性护理。利巴韦林虽然在体外有效地限制病毒复制，但 没有确凿证据表明在减轻HCPS严重程度方面是有效的。 最近对新城疫病毒感染者的一项研究表明，轻度疾病与 入院时抗SN病毒中和抗体水平高(&gt；1：800)(13)。 此外，在同一时间点，NT抗体滴度较低(si：200)与严重疾病和 高死亡率。事实上，将恢复的HCPS患者的免疫血浆注射给鹿小鼠是 足以保护这些水库啮齿动物免受病毒攻击，如果在攻击之前给药 (Rafael Medina和Brian Hjelle，未发布的数据)。在另一项研究中，ANDV特异性NT抗体 (从猕猴身上恢复的)能够保护仓鼠免受致命疾病的侵袭 给药(34)。这些抗体还能够交叉中和SNV和黑溪运河 病毒(北美的另一种HCPS代理)。在SNV、汉滩病毒、Puumala病毒的啮齿动物模型中 (PUUV)和首尔病毒感染，母体获得或被动转移的抗体就足够了 预防感染和/或改善疾病(18、21、27、37-39、44、71、72、82)。基于这些 据观察，我们假设被动注射NT抗体可能是一种有效的 减少/预防由HCPS病引起的发病率和死亡率的治疗干预 感染新城疫病毒和新城疫病毒。

An effective vaccine for the prevention of HCPS in the Americas has not been developed and treatment is limited to supportive care at present. Ribavirin, while effective at restricting viral replication in vitro, has not conclusively been shown to be efficacious in alleviating HCPS severity. A recent study of SNV-infected patients demonstrated that mild disease is significantly associated with high levels (>1:800) of anti-SN virus neutralizing (Nt) antibodies at the time of hospital admission(13). Furthermore, low titers (si :200) of Nt antibody at this same time point correlate with severe disease and high mortality. Indeed, administration of immune plasma from recovered HCPS patients to deer mice is sufficient to protect these reservoir rodents from viral challenge if it is administered prior to challenge (Rafael Medina and Brian Hjelle, unpublished data). In a separate study, ANDV-specific Nt antibodies (recovered from Rhesus macaques) were able to protect hamsters from lethal disease when passively administered(34). These antibodies were also able to cross-neutralize both SNV and Black Creek Canal virus (another HCPS agent in North America). In rodent models of SNV, Hantaan virus, Puumala virus (PUUV), and Seoul virus infection, maternally-acquired or passively transferred antibodies are sufficient to prevent infection and/or ameliorate disease(18, 21, 27, 37-39, 44, 71, 72, 82). Based upon these observations, we hypothesize that passive administration of Nt antibodies may be an effective therapeutic intervention to reduce/prevent morbidity and mortality due to HCPS disease resulting from infection with SNV and ANDV.